Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes.  In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies.  Simon now serves on the boards of several organizations, including RARE-X, Global Genes, Uncommon Cures, the Cures Acceleration Network Review Board at the NIH, Cure AHC, Hope For Annabel, and the Genomic Answers for Children’s Health Alliance.   Simon earned bachelor’s and master’s degrees in economics from Cambridge University and a bachelor’s degree in finance from the University of South Africa.